KG
CRL icon

Kilter Group’s Charles River Laboratories CRL Stock Holding History

Kilter Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681 Buy
3
+2
+200% +$356 ﹤0.01% 1344
2026
Q1 		$173 Sell
1
-2
-67% -$371 ﹤0.01% 1487
2025
Q4 		$599 Hold
3
– – ﹤0.01% 1165
2025
Q3 		$470 Sell
3
-11
-79% -$1.75K ﹤0.01% 1067
2025
Q2 		$2.13K Buy
+14
New +$1.87K ﹤0.01% 600

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Kilter Group's CRL Position: Q2 2026 in Review

Kilter Group increased its Charles River Laboratories (CRL) stake by 200% in Q2 2026, buying an estimated $356 and bringing the position to 3 shares worth $681. The position accounts for ﹤0.01% of the portfolio, ranked #1344.

Kilter Group first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.13K in Q2 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Kilter Group held 3 shares of Charles River Laboratories worth $681 as of Q2 2026.
  • Kilter Group bought 2 Charles River Laboratories shares in Q2 2026, an estimated $356.
  • Charles River Laboratories made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #1344 holding.
  • Kilter Group first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • Kilter Group's Charles River Laboratories position peaked at $2.13K in Q2 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.